Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1955 1
1962 1
1975 2
1979 2
1980 26
1981 730
1982 1854
1983 2891
1984 3882
1985 4947
1986 5405
1987 5863
1988 6029
1989 6561
1990 6942
1991 6712
1992 5897
1993 5961
1994 5896
1995 5653
1996 4958
1997 4672
1998 4704
1999 4333
2000 4516
2001 4756
2002 4336
2003 4561
2004 4764
2005 5477
2006 5650
2007 6373
2008 6856
2009 7480
2010 7626
2011 6190
2012 4871
2013 4572
2014 4611
2015 4556
2016 4663
2017 4814
2018 4528
2019 3786
2020 3744
2021 3652
2022 3630
2023 3337
2024 1283

Text availability

Article attribute

Article type

Publication date

Search Results

203,176 results

Results by year

Filters applied: . Clear all
Page 1
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, Gümüş M, Mar N, Loriot Y, Fléchon A, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, Homet Moreno B, van der Heijden MS; EV-302 Trial Investigators. Powles T, et al. N Engl J Med. 2024 Mar 7;390(10):875-888. doi: 10.1056/NEJMoa2312117. N Engl J Med. 2024. PMID: 38446675 Clinical Trial.
An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis.
Bissonnette R, Pinter A, Ferris LK, Gerdes S, Rich P, Vender R, Miller M, Shen YK, Kannan A, Li S, DeKlotz C, Papp K. Bissonnette R, et al. N Engl J Med. 2024 Feb 8;390(6):510-521. doi: 10.1056/NEJMoa2308713. N Engl J Med. 2024. PMID: 38324484 Clinical Trial.
Antibody-drug conjugates: Principles and opportunities.
Phuna ZX, Kumar PA, Haroun E, Dutta D, Lim SH. Phuna ZX, et al. Life Sci. 2024 Jun 15;347:122676. doi: 10.1016/j.lfs.2024.122676. Epub 2024 Apr 28. Life Sci. 2024. PMID: 38688384 Review.
A pivotal decade for bispecific antibodies?
Surowka M, Klein C. Surowka M, et al. MAbs. 2024 Jan-Dec;16(1):2321635. doi: 10.1080/19420862.2024.2321635. Epub 2024 Mar 11. MAbs. 2024. PMID: 38465614 Free PMC article.
Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells.
Guan X, Hu R, Choi Y, Srivats S, Nabet BY, Silva J, McGinnis L, Hendricks R, Nutsch K, Banta KL, Duong E, Dunkle A, Chang PS, Han CJ, Mittman S, Molden N, Daggumati P, Connolly W, Johnson M, Abreu DR, Cho BC, Italiano A, Gil-Bazo I, Felip E, Mellman I, Mariathasan S, Shames DS, Meng R, Chiang EY, Johnston RJ, Patil NS. Guan X, et al. Nature. 2024 Mar;627(8004):646-655. doi: 10.1038/s41586-024-07121-9. Epub 2024 Feb 28. Nature. 2024. PMID: 38418879
Different evasion strategies in multiple myeloma.
Wang C, Wang W, Wang M, Deng J, Sun C, Hu Y, Luo S. Wang C, et al. Front Immunol. 2024 Feb 23;15:1346211. doi: 10.3389/fimmu.2024.1346211. eCollection 2024. Front Immunol. 2024. PMID: 38464531 Free PMC article. Review.
203,176 results
You have reached the last available page of results. Please see the User Guide for more information.